Document Detail

15-F-isoprostane and 5-F-isoprostane are not triggers of myocardial preconditioning.
MedLine Citation:
PMID:  15854141     Owner:  NLM     Status:  MEDLINE    
1. Myocardial ischaemia-reperfusion in humans is associated with increased formation of 15-F(2t)-isoprostane and 5-F(2t)-isoprostane (15-F(2t)-IsoP and 5-F(2t)-IsoP, respectively). Whether this formation is relevant clinically remains controversial. The present study was performed in order to evaluate the ability of the isoprostanes 15-F(2t)-IsoP and 5-F(2t)-IsoP to reduce myocardial ischaemic injury in rat isolated heart. 2. Rats were divided into six groups. Hearts were excised, perfused retrogradely and pretreated with vehicle (ethanol 5.10(-7) and 2.10(-9) mol/L; n = 6), subjected to ischaemic preconditioning (n = 8) or pretreated with the isoprostanes 15-F(2t)-IsoP (3.10(-10) and 3.10(-7) mol/L; n = 8) or 5-F(2t)-IsoP (10(-9) mol/L; n = 8). After a 5 min treatment-5 min washout period, hearts were submitted to 30 min global ischaemia, followed by a 120 min reperfusion period. 3. The infarct-to-ventricle zone ratio was significantly reduced in ischaemic preconditioned (20.6 +/- 2.6%) compared with vehicle groups (44.5 +/- 4.3 and 51.3 +/- 2.5% in groups pretreated with 5.10(-7) or 2.10(-9) mol/L ethanol, respectively). Pretreatment with either isoprostane had no cardioprotective effect; the infarct-to-ventricle ratios were 43.1 +/- 2.2, 49.4 +/- 5.9 and 44.5 +/- 5.0% for groups treated with 3.10(-10) mol/L 15-F(2t)-IsoP, 3.10(-7) mol/L 15-F(2t)-IsoP or 10(-9) mol/L 5-F(2t)-IsoP, respectively. 4. These data provide evidence that the isoprostanes 15-F(2t)-IsoP and 5-F(2t)-IsoP are not implicated in early myocardial preconditioning at concentrations similar to those found in the human coronary sinus following coronary angioplasty.
Claire Arnaud; Jean-Luc Cracowski; Ahmed Hakim; Thierry Durand; Alexandre Guy; Diane Godin-Ribuot; Germain Bessard; Christophe Ribuot
Publication Detail:
Type:  Comparative Study; In Vitro; Journal Article    
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology     Volume:  32     ISSN:  0305-1870     ISO Abbreviation:  Clin. Exp. Pharmacol. Physiol.     Publication Date:    2005 May-Jun
Date Detail:
Created Date:  2005-04-27     Completed Date:  2006-01-17     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0425076     Medline TA:  Clin Exp Pharmacol Physiol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  350-4     Citation Subset:  IM    
Laboratoire de Pharmacologie, HP2 EA 3745, Faculté de Médecine de Grenoble, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dinoprost / analogs & derivatives*,  therapeutic use
F2-Isoprostanes / therapeutic use*
Ischemic Preconditioning, Myocardial / methods*
Myocardial Ischemia / drug therapy,  prevention & control*
Rats, Wistar
Reg. No./Substance:
0/5-F(2t)-isoprostane; 0/F2-Isoprostanes; 27415-26-5/8-epi-prostaglandin F2alpha; 551-11-1/Dinoprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Euphorbia thymifolia suppresses herpes simplex virus-2 infection by directly inactivating virus infe...
Next Document:  Mutated G-protein-coupled receptor GPR10 is responsible for the hyperphagia/dyslipidaemia/obesity lo...